Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Therapeutic product effect delayed? 61 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 61 reports of Therapeutic product effect delayed have been filed in association with INFLIXIMAB (Renflexis). This represents 0.0% of all adverse event reports for INFLIXIMAB.

61
Reports of Therapeutic product effect delayed with INFLIXIMAB
0.0%
of all INFLIXIMAB reports
2
Deaths
23
Hospitalizations

How Dangerous Is Therapeutic product effect delayed From INFLIXIMAB?

Of the 61 reports, 2 (3.3%) resulted in death, 23 (37.7%) required hospitalization.

Is Therapeutic product effect delayed Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 61 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Therapeutic product effect delayed?

ADALIMUMAB (244) TOFACITINIB (178) CARBIDOPA\LEVODOPA (168) SECUKINUMAB (162) POLYETHYLENE GLYCOL 3350 (125) RIMEGEPANT (120) TASIMELTEON (93) DUPILUMAB (90) IBUPROFEN (88) DICLOFENAC (85)

Which INFLIXIMAB Alternatives Have Lower Therapeutic product effect delayed Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Therapeutic product effect delayed Reports All Drugs Causing Therapeutic product effect delayed INFLIXIMAB Demographics